S-M Huang - Concepedia

Author

S-M Huang

United States Food and Drug Administration

Also Known As

S M Huang, S-M Huang, SM Huang

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research University of California, San Francisco

About

S-M Huang is an author at United States Food and Drug Administration specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	471
2	Public Health	2	2	127
3	Health Informatics	2	2	202
4	Engineering	1	1	76
5	Biomedical Engineering	1	1	76

S-M Huang

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK Christian Wagner, Ping Zhao, Y. Pan, CPT Pharmacometrics & Systems Pharmacology	2015	267
Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials Rupert W. Leong, Md L T Vieira, Ping Zhao, Clinical Pharmacology & Therapeutics	2012	183
The UCSF-FDA TransPortal: A Public Drug Transporter Database Kari M. Morrissey, C C Wen, Susan J. Johns, Clinical Pharmacology & Therapeutics Drug SafetyPharmaceutical ResearchDrug DevelopersMedicineDrug Information System	2012	165
The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review S-M Huang, Malcolm Rowland Clinical Pharmacology & Therapeutics	2012	148
Disruption of nNOS‐PSD95 protein–protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents SK Florio, Christine Loh, S-M Huang, British Journal of Pharmacology	2009	104
When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective S-M Huang, Robert Temple, Shifu Xiao, Clinical Pharmacology & Therapeutics NutritionRenal Impairment StudyUs FoodAdverse Drug ReactionRenal Function	2009	90
The International Transporter Consortium: A Collaborative Group of Scientists From Academia, Industry, and the FDA S-M Huang, Li Zhang, KM Giacomini Clinical Pharmacology & Therapeutics EngineeringTransport LogisticScientists From AcademiaBiomedical EngineeringTransport Sector	2009	76
PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways Manuela de Lima Toccafondo Vieira, Myeong‐Jin Kim, S Apparaju, Clinical Pharmacology & Therapeutics GeneticsGenetic EpidemiologyPharmacotherapySystem PharmacologyPhysiologically-based Pharmacokinetic Modeling	2014	65
Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time-Dependent CYP3A Inhibitor Md L T Vieira, Ping Zhao, Eva Gil Berglund, Clinical Pharmacology & Therapeutics	2012	41
The need for education in pharmacogenomics: a regulatory perspective Felix W. Frueh, Federico Goodsaid, A Rudman, The Pharmacogenomics Journal MedicinePharmacogenomicsPharmacogeneticsRegulatory PerspectivePharmacology	2005	38

Page 1